<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111978</url>
  </required_header>
  <id_info>
    <org_study_id>ENGOT-ov54/Swiss-GO-2/MATAO</org_study_id>
    <secondary_id>2019-002264-27</secondary_id>
    <secondary_id>ENGOT-ov54</secondary_id>
    <secondary_id>Swiss-GO-2</secondary_id>
    <nct_id>NCT04111978</nct_id>
  </id_info>
  <brief_title>MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)</brief_title>
  <acronym>MATAO</acronym>
  <official_title>MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Go Trial Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft Gynaekologische Onkologie Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reliable Cancer Therapies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krebsliga Schweiz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stiftung Guido Feger</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsana AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anticancer Fund, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Go Trial Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of addition of letrozole to the&#xD;
      standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor&#xD;
      (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and&#xD;
      primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of&#xD;
      the participants will receive to the standard maintenance treatment, letrozole, whilst the&#xD;
      other half receives placebo.&#xD;
&#xD;
      The study's primary hypothesis is that the treatment with letrozole increases progression&#xD;
      free survival in comparison to the maintenance standard treatment (superiority trial).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Femara (letrozole) is an extensively investigated, marketed aromatase inhibitor (AI) widely&#xD;
      used as treatment in the maintenance phase of estrogen-receptor (ER) positive breast cancer,&#xD;
      as it inhibit the synthesis of estrogens. Estrogen is a well known driver of cancer growth in&#xD;
      ER-positive tumors and a high percentage of the epithelial ovarian cancers express ER as&#xD;
      well. Of which low grade ovarian cancers demonstrates the highest level of expression,&#xD;
      supporting our strategy of a sub-group analysis (LOGOS). Therefore, letrozole in this study&#xD;
      be investigated prospectively and evaluated as maintenance therapy after standard surgical&#xD;
      and chemotherapy treatment in comparison to placebo (which is the current standard&#xD;
      maintenance treatment) in subjects with primary, ER-positive low or high grade serous or&#xD;
      endometrioid epithelial ovarian cancer (including fallopian tube and primary peritoneal&#xD;
      cancer) of FIGO Stage II-IV, whose cancer has not progressed by the end of the platinum-based&#xD;
      chemotherapy.&#xD;
&#xD;
      The objectives are to evaluate the letrozole maintenance treatment compared to placebo in&#xD;
      terms of&#xD;
&#xD;
        -  progression-free survival (PFS; primary endpoint)&#xD;
&#xD;
        -  overall survival (OS)&#xD;
&#xD;
        -  quality-adjusted progression free survival (QAPFS)&#xD;
&#xD;
        -  time to first subsequent treatment (TFST)&#xD;
&#xD;
        -  quality-adjusted time without symptoms of toxicity (Q-TWiST)&#xD;
&#xD;
        -  health related quality of life (QoL) assessed by EQ-5D-5L, FACT-ES and FACT-O&#xD;
           questionnaires&#xD;
&#xD;
      Methods: 540 for this study eligible subjects are 1:1 allocated in this randomized,&#xD;
      controlled, double-blinded, multi-centre study to either the test (letrozole) or control&#xD;
      (placebo) group. The maximum maintenance treatment duration is 5 years or until symptoms of&#xD;
      toxicity or progression of underlying disease.&#xD;
&#xD;
      Health and health-related quality of life will continuously be assessed at study entry and&#xD;
      during routine recalls which are scheduled every 12 weeks for the first 2 years, followed by&#xD;
      every 24 weeks for the next 3 years. Procedures performed to assess the participants' health&#xD;
      are the same as are performed during the regular routine ovarian cancer follow-up visits:&#xD;
      blood tests, physical as well as gynaecological examinations and may include imaging. In&#xD;
      addition, the participants are asked to complete during the study quality of life (QoL)&#xD;
      specific questionnaires and wear an activity tracker for one week just before the scheduled&#xD;
      visits. These assessments will be used for the evaluation of letrozole's efficacy and burden&#xD;
      in comparison to the standard maintenance treatment. Survival follow-up data after the&#xD;
      mainentance treatment duration of 5 years (study end) are obtained for up to another 7 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) for each study group</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>PFS defined as the time from the date of first IMP administration until the date of progression (recurrence) or death by any cause in the absence of progression.&#xD;
Assessment of progression (recurrence) is generally indicated by SYMPTOMS and will be assessed by the investigator most commonly on the basis of CT scans of the pelvis, abdomen and thorax, according to RECIST v1.1 criteria recommended and mostly presented by an elevated CA-125 level. Elevated CA-125 levels alone shouldn't be considered as progression. Progression assessment according to local standard of care, however, is similarly acceptable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) for each study group</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>OS defined for each patient as the time from the date of first IMP administration until the date of death from any cause. Patients not having an event at the time of analysis will be censored at the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-adjusted progression free survival (QAPFS) for each study group</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>QAPFS defined as the time from the date of first IMP administration until the date of progression (recurrence) or death by any cause in the absence of progression under consideration of the quality of life during this period. QAPFS incorporates progression-free survival (quantity) and quality of life during this period into a measure of net clinical benefit:&#xD;
QAPFS = PFS (years or months) x QoL (utility value).&#xD;
Utility values derived from the EQ-5D-L5 questionnaire will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent treatment (TFST) for each study group</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>TFST defined for each patient as the time from the date of first IMP administration until the date the patient started the next (second-line) subsequent anticancer treatment. Patients not receiving a subsequent anticancer treatment at the time of analysis will be censored at the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-adjusted time without symptoms of toxicity (Q-TWiST) for each study group</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>Q-TWiST defined as the Quality adjusted Time Without appearance of any Symptoms of Toxicity related to either the progression of the cancer or side effects of the trial medication from the date of first IMP administration until dead.&#xD;
The Q-TWiST analysis considers the following three health states:&#xD;
(1) the period experiencing toxicity (TOX)&#xD;
(2) the period before progression without experiencing toxicity (TWiST)&#xD;
(3) the period after relapse (REL)&#xD;
These periods are assigned preference utilities (u), which will be derived using the generic EQ-5D-5L questionnaire.&#xD;
The Q-TWiST will be calculated as the weighted sum of the time spent in each health state:&#xD;
Q-TWiST = uTox*TOX + TWiST + uRel*REL where u denotes the assigned utility for each respective health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (QoL) assessed byFunctional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) questionnaire for each study group</measure>
    <time_frame>Up to approximately 5.25 years</time_frame>
    <description>Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) is included into the study to more specifically assess the side effects from the IMPs on quality of life. The minimum value is 0, the maximum value for the specific 19 item Endocrine Symptom Subscale (ESS-19) is 76. The higher the score, the better the QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (QoL) assessed by Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire for each study group</measure>
    <time_frame>Up to approximately 5.25 years</time_frame>
    <description>In the context of this study the specific ovarian cancer symptom-oriented questionnaire Functional Assessment of Cancer Therapy - Ovarian (FACT-O) is included to assess the progression/recurrence of ovarian cancer on Quality of Life. The minimum value is 0, the maximum value including the specific Ovarian Cancer Subscale (OCS) is 152. The higher the score, the better the QOL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Ovarian Neoplasm Epithelial</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Peritoneal Neoplasms</condition>
  <condition>High-grade Serous Ovarian Carcinoma (HGSOC)</condition>
  <condition>Low-grade Serous Ovarian Carcinoma (LGSOC)</condition>
  <condition>Ovarian Endometrioid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Letrozole (aromatase inhibitor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole, 2.5 mg Femara tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet of Femara (without aromatase inhibitor), 0 mg Femara tablet, administered once daily for 5 years or progression of underlying disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5mg</intervention_name>
    <description>Aromatase inhibitor</description>
    <arm_group_label>Letrozole (aromatase inhibitor)</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet of Femara</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 18 years of age&#xD;
&#xD;
          -  Willing and able to attend the visits and to understand all study-related procedures.&#xD;
&#xD;
          -  Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high&#xD;
             grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer&#xD;
&#xD;
          -  (Interval-) debulking performed ECOG-Performance Status 0-2&#xD;
&#xD;
          -  Signed informed consents (ICF-1; ICF-2)&#xD;
&#xD;
          -  Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available&#xD;
&#xD;
          -  Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility&#xD;
             of MATAO trial)&#xD;
&#xD;
          -  At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)&#xD;
&#xD;
          -  Negative serum pregnancy test in women of childbearing potential who will get/have&#xD;
             gotten a surgical resection or radiation sterilization, prior to the intervention in&#xD;
             the therapeutical maintenance setting.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of&#xD;
             protocol&#xD;
&#xD;
          -  Women of childbearing potential (not having undergone a surgical or radiation&#xD;
             sterilization and not getting a surgical resection, prior to the intervention in the&#xD;
             therapeutical maintenance setting)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any other malignancy within the last 5 years which has impact on the prognosis of the&#xD;
             patient&#xD;
&#xD;
          -  &lt; 4 cycles of chemotherapy in total&#xD;
&#xD;
          -  Contraindications to endocrine therapy&#xD;
&#xD;
          -  Inability or unwillingness to swallow tablets&#xD;
&#xD;
          -  Patients with a known intolerance to galactose, lactase deficiency and&#xD;
             glucose-galactose malabsorption&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viola Heinzelmann-Schwarz, Prof. MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Head Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela McLaughlin, PhD</last_name>
    <phone>+41 61 328 42 04</phone>
    <email>pamela.mclaughlin@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maren Vogel, PhD</last_name>
    <phone>+41 61 3284203</phone>
    <email>maren.vogel@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viola Heinzelmann-Schwarz, Prof</last_name>
      <phone>+41 (0)61 265 58 83</phone>
      <email>viola.heinzelmann@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau AG</name>
      <address>
        <city>Aarau</city>
        <state>Kanton Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Sarlos, PD</last_name>
      <phone>+41 (0)62 838 5065</phone>
      <email>dimitri.sarlos@ksa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden AG</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Heubner, Prof.</last_name>
      <phone>+41 (0)56 486 3502</phone>
      <email>martin.heubner@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Basel Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schmid, Dr. med.</last_name>
      <phone>+41 (0)61 685 88 65</phone>
      <email>thomas.schmid@claraspital.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Medizinische Onkologie, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Zenger, Dr. med</last_name>
      <phone>+41 (0)31 632 5059</phone>
      <email>franziska.zenger@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis im Frauenzentrum Lindenhofspital</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Rothmund, Prof.</last_name>
      <phone>+41 (0)31 300 85 80</phone>
      <email>ralf.rothmund@lindenhofgruppe.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonspital Graubünden (KSGR),</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schwitter, Dr. med.</last_name>
      <phone>+41 (0)81 256 66 46</phone>
      <email>Michael.Schwitter@ksgr.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Fehr, Prof.</last_name>
      <phone>+41 (0)52 723 7255</phone>
      <email>mathias.fehr@stgag.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intidar Labidi-Galy, Dr. med.</last_name>
      <phone>+41 (0)22 372 4014</phone>
      <email>intidhar.labidi-galy@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Spital Grabs</name>
      <address>
        <city>Grabs</city>
        <zip>9472</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seraina Schmid, PD</last_name>
      <phone>+41 (0)81 772 5410</phone>
      <email>seraina.schmid@srrws.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Waadt/ CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apostolos Sarivalasis, Dr. med.</last_name>
      <phone>+41 (0)79 556 73 62</phone>
      <email>apostolos.sarivalasis@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Vigo, Dr. med.</last_name>
      <phone>+41 (0)61 925 22 13</phone>
      <email>francesco.vigo@ksbl.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Aebi, Prof.</last_name>
      <phone>+41 (0)41 205 5860</phone>
      <email>stefan.aebi@luks.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tumorzentrum Hirslanden Klinik St. Anna</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Günthert, Prof</last_name>
      <phone>+41 (0)41 208 41 13</phone>
      <email>Andreas.guenthert@hin.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Münsterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Taverna, Dr. med.</last_name>
      <phone>+41 (0)71 686 22 02</phone>
      <email>christian.taverna@stgag.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Hornung, Prof.</last_name>
      <phone>+41 (0)71 494 18 62</phone>
      <email>Rene.Hornung@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Müller, Dr. med.</last_name>
      <phone>+41 (0)52 266 3644</phone>
      <email>andreas.mueller@ksw.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Hirslanden Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Hirschi-Blickenstorfer, Dr. med.</last_name>
      <phone>+41 (0)44 387 3761</phone>
      <email>ahirschi@onkozentrum.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Gabriel, Dr. med.</last_name>
      <phone>+41 (0)44 416 20 04</phone>
      <email>natalie.gabriel@triemli.zuerich.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unispital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Wicki, Porf.</last_name>
      <phone>+41 (0)44 255 91 16</phone>
      <email>andreas.wicki@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maintenance therapy</keyword>
  <keyword>aromatase inhibitor</keyword>
  <keyword>primary ovarian cancer</keyword>
  <keyword>estrogen-receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

